To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

Clinical trial NCT03593447 · COMPLETED

Trial details

NCT number: NCT03593447
Sponsor: Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Hepatics C Virus (HCV) Genotype 1 Non-Cirrhotic Cirrhosis Treatment naïve

Start date: 2018-03-15
Primary completion: 2019-04-23
Enrollment: 133

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.